High expression of CERCAM, HS6ST2, ONECUT2, SOX12 and TMEM132A and low expression of MIA2 related to poor outcomes for progression-free survival (Figure S2) and cancer-specific survival (Table 2). This evidence concerns the gene HS6ST2 and cancer.